Clinical trial / 2016
Saffron supplementation (30 mg/d) was linked to mid-term improvements in retinal function in patients with age-related macular degeneration.
Sixty patients with wet or dry AMD were randomized to receive oral saffron 30 mg/day or placebo for 6 months. In dry AMD, no statistically significant difference in OCT results was seen at 6 months (P = 0.282), though ERG results significantly increased between groups at 3 months (P = 0.027). In wet AMD, OCT results decreased significantly between groups at follow-up (P = 0.05), and ERG findings increased significantly at 3 months (P = 0.01), though this ERG change decreased by 6 months (P = 0.213).
- Study type
- Double-blind, placebo-controlled, randomized trial
- Who was studied
- 60 patients with wet or dry age-related macular degeneration (AMD)
- What was measured
- OCT, ERG amplitude, and implicit time
THE PAPER
Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial.
Lashay A, Sadough G, Ashrafi E, Lashay M, Movassat M, Akhondzadeh S. Med Hypothesis Discov Innov Ophthalmol, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.